Neostigmine Methylsulfate

Parasympathomimetic (Cholinesterase Inhibitor) Quaternary Ammonium Compound

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IV 0.01-0.04 mg/kg (for reversal of neuromuscular blockade) Single dose; may repeat as needed Duration: As needed
Notes: For myasthenia gravis: 0.02-0.04 mg/kg IV for diagnosis; for chronic therapy, oral pyridostigmine is preferred, but neostigmine can be used parenterally at 0.01-0.04 mg/kg q6-8h.
Dog IM/SC 0.01-0.04 mg/kg q6-8h Duration: As needed
Notes: For gastrointestinal atony or myasthenia gravis when oral therapy is not possible.
Cat IV 0.01-0.02 mg/kg (for reversal of neuromuscular blockade) Single dose Duration: As needed
Notes: For myasthenia gravis: 0.01-0.02 mg/kg IV for diagnosis; chronic therapy usually with pyridostigmine.
Horse IV 0.02-0.04 mg/kg (for reversal of neuromuscular blockade) Single dose Duration: As needed
Notes: For ileus: 0.02-0.04 mg/kg IV or SC q4-6h, but use with caution due to risk of colic.
Cattle SC/IM 0.02-0.04 mg/kg q4-6h Duration: As needed
Notes: For ruminal atony; monitor for signs of cholinergic toxicity.
Small Ruminants SC/IM 0.02-0.04 mg/kg q4-6h Duration: As needed
Notes: For ruminal atony; use with caution.
Rabbit SC/IM 0.01-0.02 mg/kg q8-12h Duration: As needed
Notes: For gastrointestinal stasis; use with supportive care.

Clinical Indications & Species Uses

General Indications
  • Reversal of non-depolarizing neuromuscular blocking agents
  • Treatment of myasthenia gravis
  • Stimulation of gastrointestinal motility in cases of atony or ileus
  • Diagnostic agent for myasthenia gravis (tensilon test)
Dog (Canine)
  • Treatment of myasthenia gravis
  • Reversal of non-depolarizing neuromuscular blocking agents
  • Management of gastric atony and ileus (adjunctive)
  • Diagnosis of myasthenia gravis (tensilon test)
Cat (Feline)
  • Treatment of myasthenia gravis
  • Reversal of non-depolarizing neuromuscular blocking agents
  • Management of gastric atony and ileus (adjunctive)
Horse (Equine)
  • Treatment of postoperative ileus
  • Reversal of non-depolarizing neuromuscular blocking agents
  • Management of gastric atony
  • Treatment of myasthenia gravis (rare)
Cattle (Bovine)
  • Treatment of ruminal atony and gastrointestinal stasis
  • Reversal of non-depolarizing neuromuscular blocking agents (rarely used)
Small Ruminants (Sheep / Goat)
  • Treatment of ruminal atony and gastrointestinal stasis
  • Reversal of non-depolarizing neuromuscular blocking agents (rarely used)
Rabbit & Small Mammals
  • Treatment of gastrointestinal stasis (adjunctive)
  • Reversal of non-depolarizing neuromuscular blocking agents (rarely used)
Exotic & Other Species
  • Reptiles: may be used for gastrointestinal motility disorders (limited data)
  • Small mammals: adjunctive treatment for ileus

Pharmacology & Mechanism of Action

Drug Class: Parasympathomimetic (Cholinesterase Inhibitor) | Pharmacological Group: Quaternary Ammonium Compound

Mechanism of Action: Neostigmine methylsulfate is a reversible cholinesterase inhibitor that prevents the breakdown of acetylcholine (ACh) at cholinergic synapses. By inhibiting acetylcholinesterase, it increases the concentration and duration of ACh at the neuromuscular junction and other cholinergic sites, thereby enhancing cholinergic transmission. It has a direct stimulatory effect on nicotinic receptors at the neuromuscular junction and muscarinic receptors at autonomic effector sites. Its quaternary ammonium structure limits its penetration into the central nervous system, making its effects primarily peripheral.

Pharmacodynamics: Neostigmine produces effects similar to those of direct-acting cholinergic agonists but through indirect mechanisms. It enhances gastrointestinal motility, increases salivary and bronchial secretions, causes miosis, bradycardia, and bronchoconstriction. At the neuromuscular junction, it improves muscle contraction in conditions like myasthenia gravis and reverses the effects of non-depolarizing neuromuscular blocking agents. The onset of action after IV administration is rapid (within minutes), and the duration is relatively short (30-90 minutes) depending on the dose and species.

⚑ Pharmacokinetics Summary

Absorption: Neostigmine is poorly absorbed from the gastrointestinal tract due to its quaternary ammonium structure. Oral bioavailability is low and erratic. Parenteral administration (IV, IM, SC) provides reliable absorption. Onset of action after IM or SC injection is within 10-30 minutes.
Distribution: It distributes widely in extracellular fluids but does not cross the blood-brain barrier to a significant extent. It crosses the placenta minimally. Volume of distribution is relatively small.
Metabolism: Neostigmine is metabolized by plasma esterases and hepatic metabolism. It is also hydrolyzed by acetylcholinesterase.
Excretion: Excretion is primarily renal, with both unchanged drug and metabolites excreted in urine. Biliary excretion also occurs. In animals with renal impairment, elimination may be prolonged.
Half-Life: In dogs, the elimination half-life is approximately 0.5-1 hour. In horses, it is about 0.5-1.5 hours. In ruminants, similar half-lives are observed.
Bioavailability: Oral bioavailability is low (approximately 2-5% in dogs). Parenteral administration yields complete bioavailability.
Protein Binding: Protein binding is low, approximately 15-25%.

Available Formulations & Strengths

Injectable Solution 0.5 mg/mL, 1 mg/mL (IV, IM, SC)
Oral Tablet (as bromide salt) 15 mg, 30 mg (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to neostigmine or other cholinesterase inhibitors
  • Mechanical gastrointestinal or urinary obstruction
  • Peritonitis
  • Concurrent use with depolarizing neuromuscular blocking agents (e.g., succinylcholine)
  • Bradycardia or hypotension (unless atropine is available)
  • Asthma or severe bronchoconstriction
Warnings & Clinical Precautions:
  • Use with caution in animals with cardiac disease, especially bradyarrhythmias.
  • Have atropine available to counteract muscarinic effects.
  • In animals with myasthenia gravis, overdosage can cause cholinergic crisis, which is difficult to distinguish from myasthenic crisis.
  • Use with caution in animals with renal impairment, as excretion may be reduced.
  • In horses, use with caution due to risk of colic and hypermotility.
  • In ruminants, monitor for signs of excessive salivation and bloat.
  • Not for use in animals with known hypersensitivity.
  • Avoid extra-label use in food animals without proper withdrawal times.

Adverse Effects & Reactions

Common:

  • Salivation
  • Lacrimation
  • Urination
  • Defecation
  • Bradycardia
  • Bronchoconstriction
  • Miosis
  • Muscle fasciculations
  • Nausea and vomiting

Serious / Severe:

  • Cholinergic crisis (muscle weakness, respiratory paralysis)
  • Severe bradycardia or cardiac arrest
  • Bronchospasm and respiratory distress
  • Seizures (rare, due to central effects if blood-brain barrier is compromised)

Rare:

  • Hypersensitivity reactions
  • Allergic dermatitis
  • Arrhythmias

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Atropine Atropine antagonizes the muscarinic effects of neostigmine, used to manage bradycardia and excessive secretions. Moderate
Depolarizing neuromuscular blockers (e.g., succinylcholine) Neostigmine may prolong or enhance the effects of depolarizing blockers; concurrent use is contraindicated. High
Non-depolarizing neuromuscular blockers (e.g., atracurium, vecuronium) Neostigmine reverses the neuromuscular blockade; used therapeutically. Moderate
Beta-blockers May increase the risk of bradycardia and hypotension. Moderate
Digoxin Neostigmine may increase the risk of bradyarrhythmias when used with digoxin. Moderate
Aminoglycoside antibiotics May antagonize the effects of neostigmine on neuromuscular transmission, potentially worsening muscle weakness. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Excessive salivation and lacrimation
  • Bradycardia and hypotension
  • Bronchoconstriction and respiratory distress
  • Muscle fasciculations and weakness
  • Vomiting and diarrhea
  • Urination and defecation
  • Cholinergic crisis with respiratory paralysis

Emergency Treatment Protocol: Immediate administration of atropine (0.02-0.05 mg/kg IV, IM, or SC) to counteract muscarinic effects. Supportive care includes oxygen therapy, fluid therapy, and respiratory support. For neuromuscular blockade, pralidoxime may be used in severe cases, but it is less effective for quaternary ammonium compounds. Monitor vital signs closely and provide symptomatic treatment.

Food Animal Withdrawal Times

πŸ₯© Meat: 7 daysπŸ₯› Milk: 3 days

Withdrawal times are not established for neostigmine in food animals; use extra-label with caution and follow local regulations. The values provided are estimates based on pharmacokinetic data and should be confirmed with regulatory authorities.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (15-30Β°C).

Light Sensitivity: Light-sensitive β€” protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep in a tightly closed container. Do not freeze.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs and cats for certain indications; not approved for food animals in the US.

Extra-Label (Off-Label) Use: In the US, extra-label use of neostigmine in food animals is permitted under AMDUCA with veterinary oversight, but requires extended withdrawal times and a valid VCPR. It is not approved for use in food animals in many countries.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Neostigmine methylsulfate is a valuable drug for managing myasthenia gravis and reversing neuromuscular blockade. It is important to differentiate between myasthenic crisis (under-treatment) and cholinergic crisis (over-treatment) in animals with myasthenia gravis; the Tensilon test can be used diagnostically. Always have atropine available when administering neostigmine. In horses and ruminants, use with caution due to the risk of gastrointestinal hypermotility and colic. For chronic therapy of myasthenia gravis, oral pyridostigmine is often preferred due to better bioavailability and convenience. Neostigmine should be used as an adjunct to supportive care in cases of ileus, not as a sole treatment. Monitor heart rate and respiratory function closely during administration.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)